{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:46:40Z","timestamp":1740167200681,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005616","name":"Allergan Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005616","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40123-022-00593-w","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T10:02:58Z","timestamp":1668247378000},"page":"341-353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety of Fixed-Combination Bimatoprost 0.03%\/Timolol 0.5% Ophthalmic Solution at 6\u00a0Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4440-1389","authenticated-orcid":false,"given":"Xinghuai","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghuai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8822-9058","authenticated-orcid":false,"given":"Aiwu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanchu","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3938-7164","authenticated-orcid":false,"given":"Minbin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7130-0102","authenticated-orcid":false,"given":"Michelle Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6392-3257","authenticated-orcid":false,"given":"Margot L.","family":"Goodkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,12]]},"reference":[{"issue":"18","key":"593_CR1","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901\u201311.","journal-title":"JAMA"},{"issue":"1","key":"593_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ophtha.2020.10.022","volume":"128","author":"SJ Gedde","year":"2021","unstructured":"Gedde SJ, Vinod K, Wright MM, et al; American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel. Primary open-angle glaucoma preferred practice pattern. Ophthalmology. 2021;128(1):71\u2013150.","journal-title":"Ophthalmology"},{"key":"593_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjophthalmol-2021-egsguidelines","volume":"105","author":"European Glaucoma Society","year":"2021","unstructured":"European Glaucoma Society. Terminology and guidelines for glaucoma, 5th edn. Br J Ophthalmol. 2021;105:1\u2013169.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"593_CR4","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.07.020705","volume":"7","author":"P Song","year":"2017","unstructured":"Song P, Wang J, Bucan K, Theodoratou E, Rudan I, Chan KY. National and subnational prevalence and burden of glaucoma in China: a systematic analysis. J Glob Health. 2017;7(2):020705.","journal-title":"J Glob Health"},{"key":"593_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12886-015-0124-x","volume":"15","author":"J He","year":"2015","unstructured":"He J, Zou H, Lee RK, et al. Prevalence and risk factors of primary open-angle glaucoma in a city of Eastern China: a population-based study in Pudong New District, Shanghai. BMC Ophthalmol. 2015;15:134.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"593_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11596-014-1245-9","volume":"34","author":"H Li","year":"2014","unstructured":"Li H, Zhang YY, Liu SC, et al. Prevalence of open-angle glaucoma in southwestern China: the Yongchuan Glaucoma Study. J Huazhong Univ Sci Technol Med Sci. 2014;34(1):137\u201341.","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"issue":"6","key":"593_CR7","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1167\/iovs.11-9306","volume":"53","author":"H Zhong","year":"2012","unstructured":"Zhong H, Li J, Li C, et al. The prevalence of glaucoma in adult rural Chinese populations of the Bai nationality in Dali: the Yunnan Minority Eye Study. Invest Ophthalmol Vis Sci. 2012;53(6):3221\u20135.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"593_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/eye.2011.243","volume":"26","author":"J Sun","year":"2012","unstructured":"Sun J, Zhou X, Kang Y, et al. Prevalence and risk factors for primary open-angle glaucoma in a rural northeast China population: a population-based survey in Bin County, Harbin. Eye (Lond). 2012;26(2):283\u201391.","journal-title":"Harbin Eye (Lond)"},{"issue":"11","key":"593_CR9","doi-asserted-by":"publisher","first-page":"8250","DOI":"10.1167\/iovs.11-7472","volume":"52","author":"YB Liang","year":"2011","unstructured":"Liang YB, Friedman DS, Zhou Q, et al. Prevalence of primary open angle glaucoma in a rural adult Chinese population: the Handan eye study. Invest Ophthalmol Vis Sci. 2011;52(11):8250\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"593_CR10","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.ophtha.2011.02.050","volume":"118","author":"W Song","year":"2011","unstructured":"Song W, Shan L, Cheng F, et al. Prevalence of glaucoma in a rural northern China adult population: a population-based survey in Kailu County, Inner Mongolia. Ophthalmology. 2011;118(10):1982\u20138.","journal-title":"Ophthalmology"},{"issue":"11","key":"593_CR11","first-page":"726","volume":"40","author":"L Xu","year":"2004","unstructured":"Xu L, Chen JH, Li JJ, et al. [The prevalence and its screening methods of primary open angle glaucoma in defined population-based study of rural and urban in Beijing]. Zhonghua Yan Ke Za Zhi. 2004;40(11):726\u201332.","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"593_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2147\/OPTH.S284474","volume":"15","author":"B Beal","year":"2021","unstructured":"Beal B, Shih V, Campbell J, Veenstra D, Devine B. Comparing healthcare resource utilization and costs for patients with normal tension glaucoma across levels of severity: a retrospective cohort study. Clin Ophthalmol. 2021;15:453\u201360.","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"593_CR13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.ogla.2020.12.007","volume":"4","author":"V Shih","year":"2021","unstructured":"Shih V, Parekh M, Multani JK, et al. Clinical and economic burden of glaucoma by disease severity: a United States claims-based analysis. Ophthalmol Glaucoma. 2021;4(5):490\u2013503.","journal-title":"Ophthalmol Glaucoma"},{"issue":"4","key":"593_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ajo.2011.06.004","volume":"152","author":"R Varma","year":"2011","unstructured":"Varma R, Lee PP, Goldberg I, Kotak S. An assessment of the health and economic burdens of glaucoma. Am J Ophthalmol. 2011;152(4):515\u201322.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"593_CR15","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1185\/03007990802111068","volume":"24","author":"J Thygesen","year":"2008","unstructured":"Thygesen J, Aagren M, Arnavielle S, et al. Late-stage, primary open-angle glaucoma in Europe: social and health care maintenance costs and quality of life of patients from 4 countries. Curr Med Res Opin. 2008;24(6):1763\u201370.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"593_CR16","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.ajo.2007.02.022","volume":"143","author":"R McKean-Cowdin","year":"2007","unstructured":"McKean-Cowdin R, Varma R, Wu J, Hays RD, Azen SP. Severity of visual field loss and health-related quality of life. Am J Ophthalmol. 2007;143(6):1013\u201323.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"593_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1001\/archopht.124.1.12","volume":"124","author":"PP Lee","year":"2006","unstructured":"Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol. 2006;124(1):12\u20139.","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"593_CR18","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1136\/bjo.2005.067355","volume":"89","author":"CE Traverso","year":"2005","unstructured":"Traverso CE, Walt JG, Kelly SP, et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol. 2005;89(10):1245\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"593_CR19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1185\/030079904125004358","volume":"20","author":"C Vicente","year":"2004","unstructured":"Vicente C, Walker J, Buys Y, Einarson TR, Covert D, Iskedjian M. Association between mean intraocular pressure, disease stability and cost of treating glaucoma in Canada. Curr Med Res Opin. 2004;20(8):1245\u201351.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"593_CR20","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1185\/03007995.2015.1039504","volume":"31","author":"H Lou","year":"2015","unstructured":"Lou H, Wang H, Zong Y, Cheng JW, Wei RL. Efficacy and tolerability of prostaglandin-timolol fixed combinations: an updated systematic review and meta-analysis. Curr Med Res Opin. 2015;31(6):1139\u201347.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"593_CR21","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1185\/030079908X280626","volume":"24","author":"A Hommer","year":"2008","unstructured":"Hommer A, Wickstrom J, Friis MM, et al. A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective. Curr Med Res Opin. 2008;24(4):1057\u201363.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"593_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/IJG.0b013e3181bdb586","volume":"19","author":"RA Lewis","year":"2010","unstructured":"Lewis RA, Gross RL, Sall KN, Schiffman RM, Liu CC, Batoosingh AL. The safety and efficacy of bimatoprost\/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2010;19(6):424\u20136.","journal-title":"J Glaucoma"},{"issue":"3","key":"593_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/IJG.0b013e3181507313","volume":"17","author":"JD Brandt","year":"2008","unstructured":"Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C, Bossowska I. Bimatoprost\/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2008;17(3):211\u20136.","journal-title":"J Glaucoma"},{"issue":"5","key":"593_CR24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3760\/cma.j.issn.0366-6999.20132347","volume":"127","author":"Z Ling","year":"2014","unstructured":"Ling Z, Zhang M, Hu Y, et al. Safety and efficacy of bimatoprost\/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension. Chin Med J (Engl). 2014;127(5):905\u201310.","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"593_CR25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509\u201316.","journal-title":"Am J Ophthalmol."},{"key":"593_CR26","unstructured":"Allergan. Package leaflet: information for the user\u2014Ganfort\u00ae. Irvine, CA, USA: Allergan; 2008. https:\/\/allergan-web-cdn-prod.azureedge.net\/allerganindia\/allerganindia\/media\/allergan-india\/products\/ganfort.pdf. Accessed Oct 14, 2022."},{"key":"593_CR27","unstructured":"Bausch + Lomb. TIMOPTIC\u00ae 0.25% and 0.5% (Timolol maleate ophthalmic solution). Bridgewater, NJ, USA: Bausch + Lomb, a division of Valeant Pharmaceuticals North America LLC; 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/018086s076lbl.pdf. Accessed Oct 14, 2022."},{"key":"593_CR28","unstructured":"Allergan, an AbbVie company. LUMIGAN\u00ae (bimatoprost ophthalmic solution) 0.01% [highlights of prescribing information]. Irvine, CA, USA: Allergan; 2022. http:\/\/www.allergan.com\/assets\/pdf\/lumigan_pi.pdf. Accessed Oct 14, 2022."},{"key":"593_CR29","unstructured":"Allergan, an AbbVie company. Highlights of prescribing information\u2014LATISSE\u00ae (bimatoprost ophthalmic solution) 0.03%. Irvine, CA, USA: Allergan; 2017. https:\/\/media.allergan.com\/actavis\/actavis\/media\/allergan-pdf-documents\/product-prescribing\/20170829-LATISSE-USPI-72303US17.pdf. Accessed Oct 14, 2022."},{"issue":"10","key":"593_CR30","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/IJG.0000000000001634","volume":"29","author":"IP Singh","year":"2020","unstructured":"Singh IP, Fechtner RD, Myers JS, et al. Pooled efficacy and safety profile of netarsudil ophthalmic solution 0.02% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2020;29(10):878\u201384.","journal-title":"J Glaucoma"},{"issue":"5","key":"593_CR31","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ogla.2019.03.007","volume":"2","author":"TR Walters","year":"2019","unstructured":"Walters TR, Ahmed IIK, Lewis RA, et al. Once-daily netarsudil\/latanoprost fixed-dose combination for elevated intraocular pressure in the randomized phase\u00a03 MERCURY-2 study. Ophthalmol Glaucoma. 2019;2(5):280\u20139.","journal-title":"Ophthalmol Glaucoma"},{"key":"593_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ajo.2019.03.002","volume":"204","author":"AS Khouri","year":"2019","unstructured":"Khouri AS, Serle JB, Bacharach J, et al. Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase\u00a03 ROCKET-4 study. Am J Ophthalmol. 2019;204:97\u2013104.","journal-title":"Am J Ophthalmol"},{"key":"593_CR33","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","volume":"186","author":"JB Serle","year":"2018","unstructured":"Serle JB, Katz LJ, McLaurin E, et al. Two phase\u00a03 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116\u201327.","journal-title":"Am J Ophthalmol"},{"key":"593_CR34","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2147\/PPA.S131853","volume":"11","author":"X Sun","year":"2017","unstructured":"Sun X, Lin M, Duan X, Zhang C, Ming J. Patient satisfaction with fixed-combination bimatoprost\/timolol ophthalmic solution: a survey study in patients with glaucoma in China. Patient Prefer Adherence. 2017;11:845\u201352.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"593_CR35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.17816\/OV9169-71","volume":"9","author":"TG Rotsos","year":"2016","unstructured":"Rotsos TG, Kliafa VG, Asher KJ, Papaconstantinou D. Bimatoprost\/timolol fixed combination (BTFC) in patients with primary open angle glaucoma or ocular hypertension in Greece. Int J Ophthalmol. 2016;9(1):69\u201375.","journal-title":"Int J Ophthalmol"},{"key":"593_CR36","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.2147\/OPTH.S41885","volume":"7","author":"S Pfennigsdorf","year":"2013","unstructured":"Pfennigsdorf S, de Jong L, Makk S, et al. A combined analysis of five observational studies evaluating the efficacy and tolerability of bimatoprost\/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2013;7:1219\u201325.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"593_CR37","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1185\/03007990902816947","volume":"25","author":"C Feuerhake","year":"2009","unstructured":"Feuerhake C, Buchholz P, Kimmich F. Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study. Curr Med Res Opin. 2009;25(4):1037\u201343.","journal-title":"Curr Med Res Opin"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-022-00593-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-022-00593-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-022-00593-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T01:42:27Z","timestamp":1728351747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-022-00593-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,12]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["593"],"URL":"https:\/\/doi.org\/10.1007\/s40123-022-00593-w","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"type":"print","value":"2193-8245"},{"type":"electronic","value":"2193-6528"}],"subject":[],"published":{"date-parts":[[2022,11,12]]},"assertion":[{"value":"30 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}